Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chapman

Showing results (41-50 of 320) with videos related to

Pageof 32
Sort By:
Atherosclerosis. Supplements|February 8, 2003
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolaseAlexandros D Tselepis, M John Chapman
Experimental Brain Research|November 3, 2009
Age-related differences in visual sampling requirements during adaptive locomotionGraham John Chapman, Mark Andrew Hollands
Journal of the American College of Cardiology|April 19, 2023
Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the HorizonM John Chapman, Chris J Packard
International Journal of Law and Psychiatry|February 26, 2015
An investigation of gender differences in a representative sample of juveniles detained in ConnecticutElena L Grigorenko, Tami Sullivan, John Chapman
Indian Journal of Pediatrics|January 15, 2010
Failure of 'double catheter' techniqueVijay Palanivel, M A Anjay, John Chapman
Clinical Chemistry|September 2, 2020
LDL Cholesterol: 'The Times They Are A-Changin'M John Chapman, Philippe Giral, Patrice Therond
Circulation|October 22, 2014
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"Philippe Giral, Dominique Simon, M John Chapman
Current Opinion in Lipidology|April 26, 2020
Remnant lipoproteins: are they equal to or more atherogenic than LDL?Carlos A Aguilar Salinas, M John Chapman
European Heart Journal|January 5, 2016
The year in cardiology 2015: preventionM John Chapman, Stefan Blankenberg, Ulf Landmesser
Trends in Molecular Medicine|August 16, 2011
Biological activities of HDL subpopulations and their relevance to cardiovascular diseaseLaurent Camont, M John Chapman, Anatol Kontush
Pageof 32

Showing results (41-50 of 320) with videos related to

Sort By:
Pageof 32
Atherosclerosis. Supplements|February 8, 2003
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolaseAlexandros D Tselepis, M John Chapman
Experimental Brain Research|November 3, 2009
Age-related differences in visual sampling requirements during adaptive locomotionGraham John Chapman, Mark Andrew Hollands
Journal of the American College of Cardiology|April 19, 2023
Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the HorizonM John Chapman, Chris J Packard
International Journal of Law and Psychiatry|February 26, 2015
An investigation of gender differences in a representative sample of juveniles detained in ConnecticutElena L Grigorenko, Tami Sullivan, John Chapman
Indian Journal of Pediatrics|January 15, 2010
Failure of 'double catheter' techniqueVijay Palanivel, M A Anjay, John Chapman
Clinical Chemistry|September 2, 2020
LDL Cholesterol: 'The Times They Are A-Changin'M John Chapman, Philippe Giral, Patrice Therond
Circulation|October 22, 2014
Letter by Giral et al regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)"Philippe Giral, Dominique Simon, M John Chapman
Current Opinion in Lipidology|April 26, 2020
Remnant lipoproteins: are they equal to or more atherogenic than LDL?Carlos A Aguilar Salinas, M John Chapman
European Heart Journal|January 5, 2016
The year in cardiology 2015: preventionM John Chapman, Stefan Blankenberg, Ulf Landmesser
Trends in Molecular Medicine|August 16, 2011
Biological activities of HDL subpopulations and their relevance to cardiovascular diseaseLaurent Camont, M John Chapman, Anatol Kontush
Pageof 32